ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022
Leptomeningeal Metastases: New Opportunities in the Modern Era.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Intrathecal immune checkpoint inhibitors as adjunctive therapy for leptomeningeal disease: A case series and systematic review.Neurosurgical review · 2026Pooled it
- Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.Nature cancer · 2026Article
- Significance of Positive Cerebrospinal Fluid Cytology (Leptomeningeal Metastasis) in Central Nervous System Metastasis - A Multicentre Clinicopathological Review.Pathology international · 2026Article
- Article
- Pathophysiology and treatment of leptomeningeal metastases in lung cancer.Translational lung cancer research · 2026Review
- Advances in Ommaya reservoir-based intrathecal therapy for leptomeningeal metastasis from non-small cell lung cancer: a systematic review.Frontiers in oncology · 2026Review
- Clinical outcomes of intrathecal anti-PD-1 therapy with or without whole-brain radiotherapy in melanoma leptomeningeal metastasis: a multicenter retrospective study.Frontiers in immunology · 2026Article
- Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study).Neuro-oncology · 2025Article
- Tumoroid Model Reveals Synergistic Impairment of Metabolism by Iron Chelators and Temozolomide in Chemo-Resistant Patient-derived Glioblastoma Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Emerging clinical applications of single-cell RNA sequencing in oncology.Nature reviews. Clinical oncology · 2025Review
- Leptomeningeal Disease: Current Approaches and Future Directions.Current neurology and neuroscience reports · 2025Review
- Brain metastases from lung cancer: recent advances and novel therapeutic opportunities.Discover oncology · 2025Review
- The covariance environment defines cellular niches for spatial inference.Nature biotechnology · 2025Article
- Skull bone marrow and skull meninges channels: redefining the landscape of central nervous system immune surveillance.Cell death & disease · 2025Review
- Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities.Cancer metastasis reviews · 2024Review
- Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.Neuro-oncology · 2024Review
- Leptomeningeal Carcinomatosis in a Young Patient With Colorectal Cancer: A Case Report.Cureus · 2024Article
- Ventriculoperitoneal shunting with an on-off valve for patients with leptomeningeal metastases and intracranial hypertension.Neuro-oncology practice · 2024Article
- Article
- Development of a Triple-Negative Breast Cancer Leptomeningeal Disease Model in Zebrafish.Cells · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Leptomeningeal metastases arise from cancer cell entry into the subarachnoid space, inflicting significant neurologic morbidity and mortality across a wide range of malignancies. The modern era of cancer therapeutics has seen an explosion of molecular-targeting agents and immune-mediated strategies for patients with breast, lung, and melanoma malignancies, with meaningful extracranial disease control and improvement in patient survival. However, the clinical efficacy of these agents in those with leptomeningeal metastases remains understudied, due to the relative rarity of this patient population, the investigational challenges associated with studying this dynamic disease state, and brisk disease pace. Nevertheless, retrospective studies, post hoc analyses, and small prospective trials in the last two decades provide a glimmer of hope for patients with leptomeningeal metastases, suggesting that several cancer-directed strategies are not only active in the intrathecal space but also improve survival against historical odds. The continued development of clinical trials devoted to patients with leptomeningeal metastases is critical to establish robust efficacy outcomes in this patient population, define drug pharmacokinetics in the intrathecal space, and uncover new avenues for treatment in the face of leptomeningeal therapeutic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.